Results
Type
Country of origin
Qualifications

Trastuzumab | compare suppliers & send inquiries for free

Here you will find a list of producers, manufacturers and traders of Trastuzumab. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
JINLAN Pharm-Drugs Technology Co., Ltd.

MOQ: 1 g
Type: Producer
Origin: China
China
Biocon


Type: Producer
Origin: India
India
Sandoz


Type: Producer
Origin: Austria
Austria
Celltrion


Type: Producer
Origin: South Korea
South Korea

Looking for Trastuzumab 180288-69-1?

API | Excipient name:
Trastuzumab 
Synonyms:
 
Cas Number:
180288-69-1 
DrugBank number:
DB00072 
Unique Ingredient Identifier:
P188ANX8CK

About Trastuzumab

So, what does it do? Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody 6 that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER-2 protein in tumours. It is suggested that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal proliferation of cancer cells Trastuzumab binds to HER2 and suppresses cancer cells growth, proliferation, and survival directly and indirectly In December 2017, FDA approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). It displays biosimilar properties as Herceptin according to clinical data.

While Ogivri is the first biosimilar approved in the USA for the treatment of breast cancer or stomach cancer, it is the second biosimilar approved in the USA for the treatment of cancer. Herzuma (trastuzumab-pkrb) is a biosimilar drug approved in December 2018 for the treatment of HER2-overexpressing breast cancer. KANJINTI (trastuzumab-anns) is another biosimilar approved by the FDA in June 2019.

You can ask the supplier about all relevant certificates for the product such as CoA, Safety Data Sheet and DMF.

Trastuzumab manufacturers | traders | suppliers
We have 4 companies offering Trastuzumab from 4 different countries.

Get in contact with the supplier of your choice:

  • JINLAN Pharm-Drugs Technology Co., Ltd. from China
  • Biocon from India
  • Sandoz from Austria
  • Celltrion from South Korea

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.